Washington-based AI-powered synthetic biology company AbSci has entered into a multi-program collaboration with a stealth-mode biotech company (name undisclosed) to develop novel antibody therapeutics for a number of disease indications. The terms and financial details of the partnership have not been disclosed.
The partnership will leverage AbSci’s Bionic Protein platform to identify up to seven bionic antibodies containing non-standard amino acids (nsAA) to accelerate the identification of novel antibody-drug conjugate (ADC) candidates.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.